Committee Clear On Need For Fracture Data For New Calcitonin Drugs

A March 5 FDA advisory panel gave a mixed assessment of whether nasal spray formulations of the products should remain on the market for postmenopausal osteoporosis, but overwhelmingly agreed that new versions should meet a higher efficacy standard.